A comprehensive view of Generics/Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Lupin launches formoterol fumarate inhalation solution in US; drug is generic equivalent of Mylan’s Perforomist inhalation solution, which has estimated annual sales of US$268.0M in the US
Published: November 30, 2022 by PharmaBiz
McKinsey projects value of global biosimilar market could more than triple to US$74B by 2030; the more than 55 blockbuster biologics coming off patent protection in US and Europe over the next decade account for over US$270B in expected peak annual sales
Published: November 28, 2022 by Reuters
US Senator Mike Lee introduces proposal to end FDA biosimilar switching studies, make all approved biosimilars interchangeable; FDA has granted interchangeable status to only four of 39 biosimilars it has approved
Published: November 23, 2022 by FiercePharma
FDA grants Eli Lilly’s insulin simulacrum Rezvoglar with an interchangeability tag allowing product to be swapped for its brand-name counterpart at pharmacy; biosimilars offer lower-cost alternatives to high-cost biologics
Published: November 21, 2022 by FiercePharma
Fitch: Europe's generic pharmaceutical manufacturing at risk of migrating out to markets with cheaper overheads, such as India and China, due to sharply rising energy costs and restrictive pricing laws in European markets
Published: November 15, 2022 by Fitch Solutions Sector Intelligence

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count